FDA faces a reputation crisis amid Trump pressure for fast COVID action—and that's bad news for pharma

FDA faces a reputation crisis amid Trump pressure for fast COVID action—and that's bad news for pharma: The flip-flop emergency approval of convalescent plasma by the FDA sparked a social media wildfire of criticism—and cast a shadow on the agency’s reputation. Many criticized the FDA and Commissioner Stephen Hahn over the plasma EUA for COVID-19 patients and the appearance of President Trump's involvement.